Ítem
Acceso Abierto

Identification and antifungal susceptibility patterns of reference yeast strains to novel and conventional agents: a comparative study using CLSI, EUCAST and Sensititre YeastOne methods

Mostrar el registro sencillo de la publicación
dc.creatorMercer, Derryspa
dc.creatorWelsc, Jeremyspa
dc.creatorHolzapfe, Marionspa
dc.creatorCeballos Garzón, Carlos Andrésspa
dc.date.accessioned2025-07-21T16:45:22Z
dc.date.available2025-07-21T16:45:22Z
dc.date.created2025-04-01spa
dc.date.issued2025-04-01spa
dc.description.abstractObjectives: The aim of this study was to identify and determine the MICs of 13 antifungal drugs, including the novel agents ibrexafungerp, manogepix and rezafungin, against 22 laboratory reference strains from 14 different Candida spp. and allied yeast genera using the EUCAST, CLSI and Sensititre™ YeastOne™ (SYO) methods. Results: Complete agreement between molecular and proteomics methods was observed for identification. The compounds with the greatest in vitro activity, as indicated by the lowest geometric mean MIC (GM), were manogepix (GM: 0.01), isavuconazole (GM: 0.05) and rezafungin (GM: 0.03–0.07). The overall essential agreement (EA) (within ±0 to ±2 2-fold dilutions) between the reference methods, EUCAST and CLSI, was 95%, with results ranging from 82% (ibrexafungerp) to 100% (amphotericin B, anidulafungin, fluconazole, 5-flucytosine and micafungin). Regarding EA for EUCAST and CLSI compared with SYO, values were 91% and 89%, respectively. Nevertheless, when the MIC values were transformed into log2, significant differences were observed (e.g. fluconazole, ibrexafungerp and 5-flucytosine). At the species level, Candidozyma auris and Candida duobushaemulonii exhibited the highest number of cases with significant differences when comparing the three techniques for each antifungal. Conclusions: The high EA observed reinforces the reliability of EUCAST, CLSI and SYO in guiding antifungal therapy. However, the differences in EA, particularly for ibrexafungerp and 5-flucytosine, highlight the importance of continued evaluation of these methodologies to ensure consistency. Given that antifungal susceptibility testing plays a critical role in treatment decisions, understanding these variations is essential to prevent potential misclassification of susceptibility profiles, which could impact clinical outcomes.eng
dc.format.mimetypeapplication/pdfspa
dc.identifier.doihttps://doi.org/10.1093/jacamr/dlaf040spa
dc.identifier.issn2632-1823spa
dc.identifier.urihttps://repository.urosario.edu.co/handle/10336/46080
dc.language.isoengspa
dc.publisherJARspa
dc.relation.ispartofJAC-Antimicrobial Resistance, Volume 7, Issue 2, April 2025spa
dc.relation.urihttps://watermark.silverchair.com/dlaf040.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAA1QwggNQBgkqhkiG9w0BBwagggNBMIIDPQIBADCCAzYGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMJTJmeAnTc4jUNsQFAgEQgIIDBz-BnerRASS1y5KaD_xYyDHTj-OCwSbXSXyJD0AudTsmzAZYX-C7WNuv-fRGFbMmWN41OJWreq1f3iUiyygrZRzZsdBx1-ZT6E_TIiDRlkFNCe4wq4WryXnPfTPjB2i1fC-7IHnTMMN_9MK2_3AwW4SMyO1BH5DNmJEODkbY11jpkK8eV6STOofkjH6RZTJ-RJYfIgaiJShVMCMcMCH5xuh6P7oJ39-B4WESPkCh_Xeqc-vKBLgZsw30O2a7HBCuac8A1cqojN1cQYz4rXcui9_M1OjXUFA6a3J-vNZMXlpcH1vGgcUvJgKVz4q39KrwZzY5_TU5zRSIL-TqZlHkE96dGnPOgWjf0XG_wkQ2f620WG11satfvM3VQC2_rvv_HoFwwA5AUL7s3gB1FUdg-wAoAz05YDmtiZNUuFkEAgRtPmYHRNbJGhjUr2mGsP_8Yha4yT-ZaLKbu36tIIARU95Nm-L8it1EN6GCF1l5Ez8J3SDsL2v_attEuTfZA66GXGABxZZa-96Q1e0JZOs2SgYBxyyZC_5krhUAl3WGpNaguIU1ffRlLRmFRK0K3MhHxyoNuzZZYmvVV1FEqo_PJ-hlcY_wH97HIfcvgNfPgwbXlJpuQ16gMkVimr3T1m3didv7LbKOJJ_sAXPizwkp6h7XdGePdg3T-Mstkbl5PutFbPFW8g10OedjiFJt-hNiU5slVW56uO0UHGCLBBZke1xVimJZH4EWVERXnihelHlaZjg2osOkoDB7afAhyB0UKAjgF23qZuqJ5NBWVEZCxB28iNfZml5ZyuOtmC0YwKYlzQbCVqzf5L-a0jx50DkLgANMFHXnQ2BOmnHuoQ9o_3smvot7DBRgZp_mWfre1Blk3yeP_6BSsW0iCyZDjv46C3Ilq1ejCaq55A7atDG862pNCzUafaB8GJ2zbMQyoAFR-oVdXXMwUyySbu1yTwR6a6ec8oexyy6WZpl6q94T0qlrpOuIscWeygoE9vDXMIdq4wdUAFSxwAqR0TSPTs87cWh1MARtZoYspa
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internationalspa
dc.rights.accesRightsinfo:eu-repo/semantics/openAccessspa
dc.rights.accesoAbierto (Texto Completo)spa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/spa
dc.sourceJAC Antimicrob Resistspa
dc.source.instnameinstname:Universidad del Rosariospa
dc.source.reponamereponame:Repositorio Institucional EdocURspa
dc.subject.keywordAntifungal Drugseng
dc.subject.keywordMICseng
dc.subject.keywordIbrexafungerpeng
dc.subject.keywordManogepixeng
dc.subject.keywordRezafungineng
dc.subject.keywordCandida sppeng
dc.subject.keywordYeast Generaeng
dc.subject.keywordEUCASTeng
dc.subject.keywordCLSIeng
dc.subject.keywordSensititre YeastOneeng
dc.subject.keywordMolecular Methodseng
dc.subject.keywordProteomics Methodseng
dc.subject.keywordIn Vitro Activityeng
dc.subject.keywordGeometric Mean MICeng
dc.subject.keywordIsavuconazoleeng
dc.subject.keywordEssential Agreementeng
dc.subject.keywordAmphotericin Beng
dc.subject.keywordAnidulafungineng
dc.subject.keywordFluconazoleeng
dc.subject.keyword5-Flucytosineeng
dc.subject.keywordMicafungineng
dc.subject.keywordLog2 Transformationeng
dc.subject.keywordCandidozyma auriseng
dc.subject.keywordCandida duobushaemuloniieng
dc.subject.keywordAntifungal Therapyeng
dc.subject.keywordSusceptibility Testingeng
dc.subject.keywordTreatment Decisionseng
dc.subject.keywordMisclassificationeng
dc.subject.keywordSusceptibility Profileseng
dc.subject.keywordClinical Outcomeseng
dc.titleIdentification and antifungal susceptibility patterns of reference yeast strains to novel and conventional agents: a comparative study using CLSI, EUCAST and Sensititre YeastOne methodsspa
dc.typearticlespa
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersionspa
dc.type.spaArtículo de Investigaciónspa
Archivos
Bloque original
Mostrando1 - 1 de 1
Miniatura
Nombre:
Identification_and_antifungal_susceptibility_patterns.pdf
Tamaño:
508.4 KB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
Colecciones
Artículos